MacroGenics' CEO will discuss the company’s cancer therapeutics at the Stifel Healthcare Conference on November 13, 2025.
Quiver AI Summary
MacroGenics, Inc., a biopharmaceutical company specializing in antibody-based cancer therapies, announced that its President and CEO, Eric Risser, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on November 13, 2025, at 4:00 pm ET in New York City. The event will be accessible via a webcast on the Investor Relations section of MacroGenics' website, with an archived replay available for 30 days. MacroGenics focuses on developing innovative monoclonal antibody therapies and has established a pipeline of product candidates from its advanced technology platforms, collaborating with various global pharmaceutical and biotechnology firms. For further details, the company's website is available.
Potential Positives
- Eric Risser, President and CEO, will participate in a prominent healthcare conference, showcasing leadership and potential visibility for the company.
- The participation in the Stifel Healthcare Conference indicates confidence and strategic engagement in the biopharmaceutical sector.
- The availability of a webcast and archived replay enhances transparency and accessibility for investors and stakeholders, fostering better communication.
- MacroGenics emphasizes its innovative monoclonal antibody technology, highlighting its commitment to research and development in cancer therapeutics, which may attract interest from investors and collaborators.
Potential Negatives
- None
FAQ
What is the purpose of MacroGenics, Inc.?
MacroGenics, Inc. focuses on developing innovative antibody-based therapeutics for cancer treatment.
Who is speaking at the Stifel 2025 Healthcare Conference?
Eric Risser, President and CEO of MacroGenics, will participate in the conference.
When will the fireside chat take place?
The fireside chat is scheduled for November 13, 2025, at 4:00 pm ET.
How can I access the webcast of the presentation?
The webcast can be accessed on MacroGenics' website under "Events & Presentations" in the Investor Relations section.
Will the webcast be available after the live event?
Yes, an archived replay of the webcast will be available on the website for 30 days.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MGNX Insider Trading Activity
$MGNX insiders have traded $MGNX stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MGNX stock by insiders over the last 6 months:
- WILLIAM K HEIDEN has made 2 purchases buying 100,000 shares for an estimated $150,515 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MGNX Hedge Fund Activity
We have seen 51 institutional investors add shares of $MGNX stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,095,599 shares (-63.0%) from their portfolio in Q2 2025, for an estimated $3,745,674
- ECOR1 CAPITAL, LLC added 1,602,717 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,939,287
- ROCK SPRINGS CAPITAL MANAGEMENT LP removed 1,145,214 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,385,708
- STATE STREET CORP removed 1,109,025 shares (-78.7%) from their portfolio in Q2 2025, for an estimated $1,341,920
- GEODE CAPITAL MANAGEMENT, LLC removed 772,650 shares (-53.1%) from their portfolio in Q2 2025, for an estimated $934,906
- JANE STREET GROUP, LLC added 511,777 shares (+207.7%) to their portfolio in Q2 2025, for an estimated $619,250
- GOLDMAN SACHS GROUP INC added 500,592 shares (+253.2%) to their portfolio in Q2 2025, for an estimated $605,716
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MGNX Analyst Ratings
Wall Street analysts have issued reports on $MGNX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 08/15/2025
- Barclays issued a "Overweight" rating on 05/14/2025
To track analyst ratings and price targets for $MGNX, check out Quiver Quantitative's $MGNX forecast page.
$MGNX Price Targets
Multiple analysts have issued price targets for $MGNX recently. We have seen 6 analysts offer price targets for $MGNX in the last 6 months, with a median target of $3.0.
Here are some recent targets:
- Robert Burns from HC Wainwright & Co. set a target price of $2.0 on 11/03/2025
- Etzer Darout from Barclays set a target price of $3.0 on 09/17/2025
- An analyst from Leerink Partners set a target price of $5.0 on 08/15/2025
- Mayank Mamtani from B. Riley Securities set a target price of $3.0 on 05/20/2025
- Stephen Willey from Stifel set a target price of $5.0 on 05/14/2025
Full Release
ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025, at 4:00 pm ET in New York, NY.
A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm . The Company will maintain an archived replay of the webcast on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
